Cargando…
Synthetic microparticles conjugated with VEGF(165) improve the survival of endothelial progenitor cells via microRNA-17 inhibition
Several cell-based therapies are under pre-clinical and clinical evaluation for the treatment of ischemic diseases. Poor survival and vascular engraftment rates of transplanted cells force them to work mainly via time-limited paracrine actions. Although several approaches, including the use of solub...
Autores principales: | Aday, Sezin, Zoldan, Janet, Besnier, Marie, Carreto, Laura, Saif, Jaimy, Fernandes, Rui, Santos, Tiago, Bernardino, Liliana, Langer, Robert, Emanueli, Costanza, Ferreira, Lino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622042/ https://www.ncbi.nlm.nih.gov/pubmed/28963481 http://dx.doi.org/10.1038/s41467-017-00746-7 |
Ejemplares similares
-
VEGF 165 Gene Therapy for Patients with Refractory Angina: Mobilization
of Endothelial Progenitor Cells
por: Rodrigues, Clarissa G., et al.
Publicado: (2013) -
The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF(165) and downregulating VEGF(165b)
por: Quan, Bingxuan, et al.
Publicado: (2023) -
VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010) -
MicroRNAs in vascular tissue engineering and post-ischemic neovascularization()
por: Caputo, Massimo, et al.
Publicado: (2015) -
The role of VEGF-A(165)b in trophoblast survival
por: Bills, Victoria L, et al.
Publicado: (2014)